

hematonosis compound library

Catalog No: #L8400

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description

Product Name	hematonosis compound library
Brief Description	<p>Hematologic diseases (hematonosis), disorders of the blood and blood-forming organs, afflict millions of Americans. In addition to hematological malignancies, such as leukemia and lymphomas, children and adolescents can suffer blood disorder, that are not classified as cancer, but may lead to severe diseases and therefore require treatment. These blood disorders include severe aplastic anemia (SAA), thalassemia, immune (idiopathic) thrombocytopenic purpura, congenital neutropenia, hemophilia, sickle-cell disease, iron deficiency anemia and various other diseases. In the past, due to the lack of effective treatments, many diseases have been called "incurable diseases". In recent years, with in-depth development of medical research, the treatment of blood diseases has been significantly improved. Modern medicine uses hormones, chemotherapy and other methods for the treatment of blood diseases, but the side effects are large, and the patient has a low cure rate and is prone to recurrence. Bone marrow transplantation for the treatment of leukemia was introduced then the cure rate of leukemia was improved. However, the bone marrow resources were very scarce, and a large part of the donated bone marrow was inconsistent with the patient's HLA, even if the transplant was successful, and the recurrence rate was as high as 70% within 5 years. Therefore, it is necessary to develop new therapies and drugs for the treatment of hematologic diseases.</p> <p>Hematonosis Compound Library from SAB provides you with compounds related to hematologic diseases that can be used for high throughput and high content screening.</p>
Storage	Powder or pre-dissolved DMSO solutions in 96 well plate with optional 2D barcodeShipped with dry ice; Stable for One year as powder, 6 months at - 20 ° C in DMSO or 12months at -80 ° C in DMSO

Application Details

Number of Compounds:126

Product Description

A unique collection of 126 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS); Effective tool for research in functions of the hematologic system and related diseases, such as hemophilia, leukemia, $\alpha\Omega\frac{1}{2}\alpha\Omega\frac{1}{2}$ -thalassemia; Safety and effectiveness of the small molecules have been demonstrated through preclinical and clinical research, and some of which are FDA approved; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; NMR and HPLC/LCMS validated to ensure high purity and quality

Note: This product is for in vitro research use only